Imagine a world where the excruciating pain of gout flares could be a thing of the past. That's the promise held by a groundbreaking new drug, Lingdolinurad (ABP-671), which has just shown remarkable results in reducing serum uric acid (sUA) levels, the culprit behind gout's agony. But here's where it gets controversial: could this drug finally offer a safer, more effective alternative to current treatments, which often fall short and carry serious risks?
A recent phase 2a study, presented at the prestigious American College of Rheumatology (ACR) Convergence 2025, revealed Lingdolinurad's potential. Led by Dr. Ullrich Schwertschlag, the research focused on adults up to 55 years old with hyperuricemia or gout, but without significant kidney issues. Participants were carefully randomized into groups receiving varying oral doses of ABP-671 (1, 2, 4, 6, or 12 mg) or a placebo. The study design was meticulous, starting with a gradual dose escalation over 9-10 days to prevent any renal strain, followed by a 7-day treatment period.
And this is the part most people miss: while 53.3% of participants experienced mild side effects, none were serious, and interestingly, these effects didn't increase with higher doses. This suggests a potentially favorable safety profile, a rare find in gout treatments. The real excitement, however, lies in the drug's effectiveness. sUA levels plummeted in a clear dose-dependent manner, with the most significant drops occurring between 3 and 9 hours after dosing. For instance, participants with gout saw their sUA levels decrease by up to 79.2% with the highest dose, compared to just 17.7% with the placebo. Hyperuricemia patients experienced similarly impressive reductions.
By 24 hours post-dose, the benefits were even more striking. Nearly all participants on the highest dose achieved sUA levels below 6.0 mg/dL, a critical threshold for managing gout, while none in the placebo group reached this milestone. These findings were further bolstered by Atom Therapeutics' presentation of phase 1 data on ABP-745, a novel colchicine analogue, which also showed promising safety and pharmacokinetic profiles.
But here's the million-dollar question: can these drugs truly revolutionize gout treatment, or are we getting ahead of ourselves? Atom's CEO, Dr. William Dongfang Shi, is optimistic, stating that these advancements bring us closer to providing meaningful relief to millions suffering from gout's debilitating effects. However, the journey from promising study results to widespread clinical use is long and fraught with challenges. Will ABP-671 and ABP-745 live up to the hype? Only time—and further rigorous trials—will tell. What’s your take? Do you think these drugs could be game-changers, or are there still too many unknowns? Share your thoughts in the comments below!
